All Stories

  1. Increased incidence and mortality from Listeria monocytogenes infection in Spain
  2. Prevalence of HTLV-1/2 infection in pregnant women in Central and South America and the Caribbean: a systematic review and meta-analysis
  3. COVID-19 mortality amongst the immunosuppresed
  4. Prospects for Controlling Hepatitis B Globally
  5. Human T-lymphotropic virus-1 infection among Latin American pregnant women living in Spain
  6. Screening for HTLV-1 infection should be expanded in Europe
  7. Low-coverage whole genome sequencing for a highly selective cohort of severe COVID-19 patients
  8. Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023)
  9. �One Health�: toward an integral ecology of health
  10. Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals
  11. Testing a vaccine candidate against Hepatitis C virus designed by combinatorial optimization
  12. HTLV infection in persons with sexually transmitted diseases in Spain
  13. HTLV-1-associated myelopathy in Spain
  14. Triple Threat: HDV, HBV, HIV Coinfection
  15. HTLV European Research Network 2023: the silent pandemic of HTLV-1 infection
  16. Mitochondrial damage as cause of long COVID
  17. Rebound in sexually transmitted infections after the COVID-19 pandemic
  18. Genetic signature detected in T cell receptors from patients with severe COVID-19
  19. Impact of the COVID-19 pandemic on hospital admissions due to viral hepatitis in Spain
  20. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions
  21. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
  22. Current Challenges for Conscientious Objection by Physicians in Spain
  23. Mental Health Crisis in the Youth and Rebound in Sexually Transmitted Infections
  24. The use of �sex� and �gender� in medical research
  25. Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis
  26. Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study
  27. Response to: Prognostic factors in hospitalized HIV-positive patients with COVID-19: correspondence
  28. The slowdown of new infections by human retroviruses has reached a plateau in Spain
  29. Safety considerations in the management of hepatitis C and HIV co-infection
  30. Coinfection with Viral Hepatitis in HIV patients in 2023
  31. Viral hepatitis in persons living with HIV in the post-COVID era
  32. Genomic Determinants of Long COVID
  33. Susceptibility to Hepatitis B Virus Infection in Adults Living in Spain
  34. Envisioning hepatitis delta cure without functional hepatitis B cure
  35. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
  36. Is SARS-CoV-2 the only cause of long-COVID?
  37. Controversy around SARS-CoV-2 Reinfections
  38. Alert for polio outbreaks in developed countries
  39. Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain
  40. Predictors of in-hospital mortality in HIV-infected patients with COVID-19
  41. Late presentation of human T-lymphotropic virus type 1 infection in Spain reflects suboptimal testing strategies
  42. Pre-Exposure Prophylaxis for viral infections other than HIV
  43. The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America
  44. International outbreak of monkeypox in men having sex with men
  45. Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases
  46. Treatment of hepatitis delta and HIV infection
  47. Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies
  48. A cure for HIV on the horizon
  49. News from CROI 2022 - caveats using antiretrovirals as HIV prophylaxis
  50. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain
  51. Providing Spiritual Care to In-Hospital Patients During COVID-19: A Preliminary European Fact-Finding Study
  52. Use of antibiotics in respiratory viral infections
  53. A greater virulent HIV-1 subtype B variant has circulated in The Netherlands since the 1990’s
  54. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection
  55. Another patient has cured HIV infection
  56. The opioid epidemic during the COVID-19 pandemic: Impact on HIV and HCV control
  57. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
  58. Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process
  59. Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain
  60. Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades
  61. New insights into the genetics of same-sex behavior
  62. Envisioning a hepatitis delta cure with new antivirals
  63. Short Communication: Impact of COVID-19 on Case Reporting for HTLV and HIV-2 in Spain
  64. Hepatitis delta in patients hospitalized in Spain (1997–2018)
  65. COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter
  66. Consideraciones sobre la infección por HTLV-1 en España
  67. Third wave of COVID-19 in Madrid, Spain
  68. The time to offer treatments for COVID-19
  69. Main differences between the first and second waves of COVID-19 in Madrid, Spain
  70. Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions
  71. COVID-19 Comes 40 Years After AIDS - Any Lesson?
  72. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials
  73. New SARS-CoV-2 Variants Challenge Vaccines Protection
  74. Clinical Outcome in Human T-Lymphotropic Virus Type 2 Carriers Following Organ Transplantation
  75. Situación epidemiológica actual de la infección por VIH-2 y HTLV-1 en España
  76. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis
  77. Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach
  78. Unveiling Long COVID-19 Disease
  79. A Key Action Plan for EDUCATION in a Global Crisis
  80. Acute Viral Hepatitis in Men Having Sex with Men
  81. Coronavirus and other airborne agents with pandemic potential
  82. Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity
  83. Long-acting antiretroviral therapy
  84. The Resurgence of Medical Ethics During the Coronavirus Disease (COVID)-19 Outbreak
  85. Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections
  86. Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain
  87. THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19
  88. Hospital admissions in individuals with HTLV-1 infection in Spain
  89. Poetry in Response to the “Disengagement Plan”: Identity, Poetics and Politics
  90. HTLV-1 infection and health outcomes
  91. HTLV-1 infection and health outcomes
  92. Tough requirements for new antiretroviral drugs
  93. Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2
  94. Advances in hepatitis B therapeutics
  95. Keeping alive enterprises while embracing unprecedented COVID-19 restrictions
  96. Multiple recombinant events in human T-cell Leukemia virus Type 1: complete sequences of recombinant African strains
  97. Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain
  98. Why such excess of mortality for COVID-19 in Spain?
  99. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT...
  100. Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain
  101. HTLV testing of solid organ transplant donors
  102. HTLV-1 infection in solid organ transplant donors and recipients in Spain
  103. Update of the statements on biology and clinical impact of occult hepatitis B virus infection
  104. A18 HIV-2 molecular epidemiology in Spain: 30 years since the first case
  105. Jérôme Lejeune passed away 25 years ago
  106. HIV co-infection in HTLV-1 carriers in Spain
  107. Hepatitis Delta Estimates in the United States Revisited
  108. Occult hepatitis B and HIV infection
  109. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
  110. Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
  111. Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain
  112. Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS
  113. Screening for retroviruses and hepatitis viruses using dried blood spots reveals a high prevalence of occult hepatitis B in Ghana
  114. Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals
  115. Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir
  116. Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain
  117. Short article
  118. Flash Smelting Copper Concentrates Spectral Emission Measurements
  119. AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities
  120. Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic
  121. Report from the International Conference on Viral Hepatitis (ICVH) – Chicago, October 2017
  122. Treatment and prevention of HIV infection with long-acting antiretrovirals
  123. Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges
  124. Hepatitis Delta Enters a New Therapeutic Era
  125. Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study
  126. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure
  127. Human T-Lymphotropic Virus Infection in Hepatitis C Virus–Antibody Positive Patients in Spain
  128. Need to Face Liver Cirrhosis after HCV Cure with Antivirals
  129. Is Ribavirin Teratogenic in Humans? No Evidence So Far
  130. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
  131. Antiretroviral treatment of HIV-2 infection
  132. Treatment of hepatitis C with new fixed dose combinations
  133. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C
  134. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study
  135. Drug interactions in HIV-infected patients treated for hepatitis C
  136. Dual antiretroviral therapy for HIV infection
  137. Human T-lymphotropic virus type 1 infection and disease in Spain
  138. HIV type 2 epidemic in Spain
  139. New antivirals for the treatment of chronic hepatitis B
  140. Characterization of Free Phenytoin Concentrations in End-Stage Renal Disease Using the Winter-Tozer Equation
  141. Hepatitis delta and HIV infection
  142. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response
  143. A loud tear — acute aortic regurgitation with an unusual presentation
  144. Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer's disease
  145. Decline and changing profile of hepatitis delta among injection drug users in Spain
  146. Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015
  147. Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C
  148. The global spread of HIV-1 subtype B epidemic
  149. Coronary angiography after successful thrombolysis — Is the recommended time interval of 24 h an important issue?
  150. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients
  151. Short article
  152. Hepatitis C virus resistance to the new direct-acting antivirals
  153. Can evolutionary constraints explain the rarity of nitrogen‐fixing trees in high‐latitude forests?
  154. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
  155. Is HIV still a special population for the treatment of hepatitis C?
  156. A machine vision system for automatic detection of parasites Edotea magellanica in shell-off cooked clam Mulinia edulis
  157. SOLAR-2: the sun also rises for cirrhotics
  158. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma
  159. MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression
  160. Prevention and management of treatment failure to new oral hepatitis C drugs
  161. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013
  162. Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience
  163. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection
  164. Delta hepatitis: new approaches to therapy
  165. Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy
  166. Infection-related and -unrelated malignancies, HIV and the aging population
  167. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials
  168. High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy
  169. HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012)
  170. Rapid Changes in Cholesterol in Chronic Hepatitis C Patients Treated with Antivirals and Potential Impacton Cardiovascular Risk
  171. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
  172. ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
  173. Epigenetic regulation of puberty via Zinc finger protein-mediated transcriptional repression
  174. Immunoregulatory Role of Myeloid-derived Cells in Inflammatory Bowel Disease
  175. Linfoma primário do coração em doente com neoplasia renal síncrona
  176. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy
  177. Hypoglycemia in a diabetic patient during hepatitis C therapy
  178. New hepatitis C therapies for special patient populations
  179. Corrigendum
  180. Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial
  181. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe
  182. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
  183. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C
  184. Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)
  185. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients
  186. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection
  187. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients
  188. Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma
  189. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study
  190. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study
  191. Tenofovir for Hepatitis Delta
  192. Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects
  193. Emerging Challenges in Managing Hepatitis B in HIV Patients
  194. Clinical Translation of Nanomedicine
  195. Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner
  196. From respiratory sensitization to food allergy: Anaphylactic reaction after ingestion of mushrooms (Agaricus bisporus)
  197. Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis
  198. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study
  199. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?
  200. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes
  201. High nevus counts confer a favorable prognosis in melanoma patients
  202. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis
  203. Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy
  204. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents
  205. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
  206. P0838 : Progression to advanced liver fibrosis in HIV/HCV-coinfected patients and prioritization of new hepatitis C therapies
  207. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study
  208. Dolutegravir for the treatment of HIV-2 infection
  209. Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs
  210. Gastrointestinal: Botulinum toxin effective in refractory gastroparesis in paediatric practice
  211. Agonist-Dependent Modulation of Cell Surface Expression of the Cold Receptor TRPM8
  212. Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
  213. Drug interactions with new hepatitis C oral drugs
  214. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis
  215. Hepatitis C cure with antiviral therapy – benefits beyond the liver
  216. Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1–Infected Patients Treated With Combined Antiretroviral Therapy
  217. STARTVerso4
  218. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
  219. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007–2012)
  220. Integrase Inhibitors
  221. Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004–2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions
  222. Advances in treating drug-resistant hepatitis B virus in HIV-infected patients
  223. Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis
  224. Ipilimumab for advanced melanoma
  225. Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease
  226. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
  227. Redefining the HIV epidemic in Nigeria
  228. Gene therapy for HIV infection
  229. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study
  230. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients
  231. PPARγ2 Pro12Ala Polymorphism Is Associated With Sustained Virological Response in HIV/HCV-Coinfected Patients Under HCV Therapy
  232. Molecular Epidemiology and Clinical Features of Human T Cell Lymphotropic Virus Type 1 Infection in Spain
  233. Braf Mutation Analysis in Cell Free Tumoral Dna (Cfdna) of Melanoma Patients: Preliminary Results from the Spanish Melanoma Group Prospective Study Gem1304
  234. Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies
  235. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
  236. Hepatitis E: una enfermedad viral emergente
  237. X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain
  238. Pharmacogenetics of antiretroviral therapy
  239. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
  240. Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy
  241. Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes
  242. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations
  243. High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance
  244. Treatment of hepatitis C in HIV patients in the new DAA era
  245. Towards hepatitis C eradication from the HIV-infected population
  246. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load
  247. Dolutegravir, abacavir and lamivudine as HIV therapy
  248. IFNL4 ss469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians
  249. Management and treatment of chronic hepatitis B in HIV-positive patients
  250. Infecciones por el virus de la inmunodeficiencia humana tipo 2 y por los virus linfotrópicos de células T humanas en España
  251. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy
  252. P751 DISTINCT VALUES OF LIVER STIFFNESS PREDICT PROGRESSION TO ADVANCED LIVER FIBROSIS IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C
  253. P1068 EFFICACY OF PROLONGED TENOFOVIR THERAPY ON HEPATITIS DELTA IN HIV-INFECTED PATIENTS
  254. P755 HEPATITIS C COINFECTION INDEPENDENTLY INCREASES CARDIOVASCULAR RISK IN HIV-INFECTED PATIENTS
  255. P1133 COMPARISON OF 24 AND 48 WEEKS OF TREATMENT WITH FALDAPREVIR AND PEGYLATED INTERFERON/RIBAVIRIN IN PATIENTS WITH DETECTABLE BUT NOT QUANTIFIABLE HCV RNA AT WEEK 4
  256. P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL
  257. P750 SPONTANEOUS HCV CLEARANCE IN HIV PATIENTS WITH CHRONIC HEPATITIS C BEARING FAVORABLE IL28B ALLELES ON ANTIRETROVIRAL THERAPY
  258. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study
  259. Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations
  260. Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients
  261. Deteriorating renal function and clinical outcomes in HIV-positive persons
  262. European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients
  263. Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons
  264. Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection
  265. Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis
  266. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction
  267. Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe
  268. Progression to advanced liver fibrosis in HIV/HCV-coinfected patients and prioritization of new hepatitis C therapies
  269. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV–HCV-coinfected patients
  270. Long-term survival and liver-related events after peginterferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C
  271. Very late HCV relapse following triple therapy for hepatitis C
  272. ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients
  273. A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington’s disease in mice
  274. Emerging antiretroviral drugs
  275. Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs
  276. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
  277. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection
  278. Associations between immune depression and cardiovascular events in HIV infection
  279. Strategic use of lamivudine in the management of chronic hepatitis B
  280. A polymorphism linked to RRAS ,SCAF1 ,IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers
  281. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study
  282. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy
  283. Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy
  284. Epidemiology of viral hepatitis
  285. Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort
  286. Treating hepatitis C in injection drug users
  287. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B
  288. Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals
  289. Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
  290. All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997–2010
  291. Faldaprevir and Deleobuvir for HCV Genotype 1 Infection
  292. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
  293. Recortes sanitarios e infección por el virus de la inmunodeficiencia humana
  294. Hepatitis B in HIV-Infected Patients
  295. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
  296. Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves
  297. Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1
  298. Update on HIV/HCV Coinfection
  299. Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia
  300. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response
  301. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients
  302. Antiretroviral drug-related toxicities – clinical spectrum, prevention, and management
  303. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain
  304. HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein
  305. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection
  306. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients
  307. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV
  308. Sequence Analysis of In Vivo Defective Interfering-Like RNA of Influenza A H1N1 Pandemic Virus
  309. Unusual manifestations of a common gastrointestinal disorder
  310. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy
  311. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes
  312. Hepatitis C therapy with HCV NS5B polymerase inhibitors
  313. Chronic Hepatitis E in HIV Patients: Rapid Progression to Cirrhosis and Response to Oral Ribavirin
  314. Hepatitis B, C, and D and HIV Infections among Immigrants from Equatorial Guinea Living in Spain
  315. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy
  316. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV–hepatitis C virus coinfected patients
  317. 985 INCREASING RATES OF ACUTE HEPATITIS C ALONG WITH HIGH RATES OF SYPHILIS IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN IN MADRID
  318. 1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY
  319. 496 CHANGES IN CIRCULATING HCV-RNA CONCENTRATIONS IN PATIENTS WITH CHRONIC HEPATITIS C IN THE ABSENCE OF ANTIVIRAL THERAPY
  320. 882 GENETIC VARIATIONS IN proprotein convertase subtilisin/kexin type 9 (PCSK9) GENE ARE ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN IN HEPATITIS C VIRUS GENOTYPE 3-INFECTED PATIENTS
  321. 1186 ITPA GENE VARIANTS PREDICT HEMOLYTIC RIBAVIRIN INDUCED ANAEMIA IN PATIENTS TREATED WITH THE INTERFERON-FREE REGIMEN OF FALDAPREVIR, BI 207127 AND RIBAVIRIN IN SOUND-C2
  322. 883 PREDICTION OF RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN BY INTERLEUKIN 28B GENOTYPE IS MODIFIED BY SNPS AT MULTIPLE GENES IN HIV/HEPATITIS C VIRUS GENOTYPE 1/4-COINFECTED PATIENTS
  323. 1220 TRIPLE COMBINATION THERAPY FOR HEPATITIS C WITH TELAPREVIR EXHIBITS GREATER EARLY ANTIVIRAL SUPPRESSION THAN WITH BOCEPREVIR REGARDLESS HIV STATUS
  324. Resistance to antiretroviral drugs
  325. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy
  326. Transcriptional Regulation of Insulin-degrading Enzyme Modulates Mitochondrial Amyloid   (A ) Peptide Catabolism and Functionality
  327. Contraindication of ART following a sperm FISH analysis, even though only 12% of the spermatozoa had enlarged heads
  328. Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism
  329. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
  330. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients
  331. The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies
  332. Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya
  333. Genetic Determinants of Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients
  334. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients
  335. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
  336. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients
  337. Liver fibrosis progression in HIV–HCV-coinfected patients treated with distinct antiretroviral drugs and impact of peginterferon-ribavirin therapy
  338. Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C
  339. The changing face of hepatitis C in the new era of direct-acting antivirals
  340. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir
  341. Insulysin
  342. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease?
  343. Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library
  344. IL28RApolymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients
  345. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients
  346. Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
  347. Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era
  348. HIV gag-specific immune response mediated by double negative (CD3+CD4−CD8−) T cells in HIV-exposed seronegative individuals
  349. Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain
  350. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected?
  351. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
  352. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics
  353. Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class
  354. KIT Mutations in a Series of Melanomas and Their Impact on Treatment With Imatinib
  355. Pharmacokinetics of new oral hepatitis C antiviral drugs
  356. Hepatitis C Therapy: Highlights From the 2012 Annual Meeting of the European Association for the Study of the Liver
  357. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study
  358. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
  359. The inaccuracy of surface-measured model-derived tibiofemoral kinematics
  360. Short Communication: Does Interleukin-28B Single Nucleotide Polymorphisms Influence the Natural History of Hepatitis B?
  361. Short Communication: RNASEL Alleles and Susceptibility to Infection by Human Retroviruses and Hepatitis Viruses
  362. Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms
  363. Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b
  364. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients
  365. Prevalence of Xenotropic Murine Leukemia Virus-Related Virus Infection in Different Risk Populations in Spain
  366. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study
  367. Cardiovascular Disease Risk in HIV Infection and Endothelial Progenitor Cells
  368. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
  369. Management of hepatitis C in HIV and/or HBV co-infected patients
  370. No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients
  371. Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study
  372. Comparison of High Ribavirin Induction Versus Standard Ribavirin Dosing, Plus Peginterferon-  for the Treatment of Chronic Hepatitis C in HIV-Infected Patients: The PERICO Trial
  373. Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor Cells
  374. Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up
  375. Cardiac Apical Aneurysm secondary to ibuprofen-induced type 1-Kounis Syndrome
  376. Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms
  377. Differences in Virological Response to Peginterferon-α Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b
  378. Definition of Advanced Age in HIV-Infection: Looking for an Age Cut-Off.
  379. Author's response: expert reviews: who are they for?
  380. A New Era for Hepatitis C—New Diagnostics Tools and New Weapons
  381. HIV and Liver Disease
  382. Infección por el VIH-2, virus linfotrópico de células T y nuevos retrovirus humanos en España
  383. Management and Treatment of Chronic Hepatitis C in HIV Patients
  384. Collapsin response mediator protein-2 phosphorylation promotes the reversible retraction of oligodendrocyte processes in response to non-lethal oxidative stress
  385. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
  386. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection
  387. B3 Identification of Neutralizing Antibodies and Their Epitopes From HIV Controllers
  388. Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting
  389. Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A
  390. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load
  391. 1376 LIVER TOXICITY OF THE MOST RECENTLY APPROVED ANTIRETROVIRAL DRUGS IN HIV-INFECTED PATIENTS - OVERALL LOW RATE BUT INCREASED IN THE PRESENCE OF CHRONIC HEPATITIS C
  392. 906 RECOGNITION OF HEPATITIS C VIRUS (HCV) MINORITY STRAINS BY COLD-PCR
  393. 1420 THE EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF BI201335 AND BI207127 IN GENOTYPE 1 HCV PATIENTS WITH CIRRHOSIS - INTERIM ANALYSIS FROM SOUND-C2
  394. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries
  395. Development of Tropical Spastic Paraparesis in Human T-Lymphotropic Virus Type 1 Carriers Is Influenced by Interleukin 28B Gene Polymorphisms
  396. Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens
  397. Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain
  398. Long-Term Use of Atazanavir in the Treament of HIV-Infected Patients
  399. Drug resistance testing in hepatitis C therapy
  400. Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir
  401. Factores sociodemográficos asociados a la progresión de la infección por VIH e impacto del TARGA en una cohorte de pacientes seroconvertores en Madrid (1986-2009)
  402. Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations
  403. Impact of IL28B gene polymorphisms on interferon- 3 plasma levels during pegylated interferon- /ribavirin therapy for chronic hepatitis C in patients coinfected with HIV
  404. Treatment failure with new hepatitis C drugs
  405. Foreign Direct Investment vs. Foreign Portfolio Investment
  406. Component-resolved diagnosis of vespid venom-allergic individuals: phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization
  407. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008–2010
  408. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression
  409. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes
  410. Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure
  411. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor
  412. Highly pathogenic avian influenza virus H5N1 controls type I IFN induction in chicken macrophage HD-11 cells: a polygenic trait that involves NS1 and the polymerase complex
  413. Pharmacogenetics of hepatitis C
  414. Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay
  415. Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes
  416. Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-Naive HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses
  417. Longitudinal Assessment of Interleukin 7 Plasma Levels in HIV-Infected Patients in the Absence of and Under Antiretroviral Therapy
  418. Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy
  419. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata
  420. La cohorte de la red española de investigación en sida y su biobanco: organización, principales resultados y pérdidas al seguimiento
  421. Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients
  422. Host genetics
  423. Infección por virus de la inmunodeficiencia humana y hepatitis víricas
  424. Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C
  425. The expansion ability but not the quality of HIV-specific CD8+ T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors
  426. HTLV infection among foreign pregnant women living in Spain
  427. Hepatitis delta in HIV-infected individuals in Europe
  428. Profilaxis preexposición en la prevención de la infección por virus de la inmunodeficiencia humana
  429. Response to: “Is the Study Power Enough to Say ‘No Difference’?” by Geib et al
  430. Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy
  431. Antiviral effect of raltegravir on HTLV-1 carriers
  432. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients
  433. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility
  434. A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy
  435. Short Communication: Severe Immune Suppression in Patients Infected with R5-Tropic HIV-1 Strains Is Associated with Increased gp120 Net Charge at Variable Regions
  436. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*
  437. An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHIEV2E Quality Control Study
  438. Comparison of Two Serological Tests for the Identification of Recent HIV Infection: Vironostika HIV-1 Microelisa and BED Capture Enzyme Immunoassay
  439. High Concordance between the Position-Specific Scoring Matrix and Geno2pheno Algorithms for Genotypic Interpretation of HIV-1 Tropism: V3 Length as the Major Cause of Disagreement: Table 1.
  440. Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: The INSIGHT FLU 002 and FLU 003 studies
  441. Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction
  442. Tuberculosis among HIV-positive patients across Europe
  443. Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain
  444. Directly acting antivirals against hepatitis C virus
  445. Prevalence and changing distribution of HTLV-1 and HTLV-2 infections in Spain
  446. Seroprevalence of HTLV infection in Spain among immigrant pregnant women
  447. Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
  448. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study
  449. Changing Rate of Non-B Subtypes and Coinfection with Hepatitis B/C Viruses in Newly Diagnosed HIV Type 1 Individuals in Spain
  450. Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients Receiving Antiretroviral Therapy
  451. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience
  452. Perspectivas futuras en el tratamiento de la hepatitis crónica C
  453. Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antire...
  454. Impact of Baseline HIV-1 Tropism on Viral Response and CD4 Cell Count Gains in HIV-Infected Patients Receiving First-line Antiretroviral Therapy
  455. Drug resistance mutations in patients infected with HIV-2 living in Spain
  456. HIV and the Liver
  457. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse
  458. European guidelines on the clinical management of HIV-1 tropism testing
  459. HCV-Specific T-Cell Responses in HIV/Hepatitis C Virus-Coinfected Patients on Highly Active Antiretroviral Therapy Are Comparable to Those Observed in Hepatitis C Virus-Monoinfected Individuals
  460. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin
  461. Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors
  462. XMRV, un nuevo retrovirus humano en busca de enfermedad
  463. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)
  464. Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group
  465. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients
  466. A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study
  467. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B
  468. Documento de consenso de GESIDA/ Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2011)
  469. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype
  470. Characterization of host genetic expression patterns in HIV-infected individuals with divergent disease progression
  471. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients
  472. 1168 SURVIVAL OF HIV AND HIV/HCV CO-INFECTED PATIENTS WITHIN INTENSIVE CARE UNIT (ICU) IN THE MOST RECENT HAART ERA
  473. 1230 IMPACT OF ANTIRETROVIRAL THERAPY ON THE VARIABILITY OF THE HCV NS5B POLYMERASE IN HIV/HCV COINFECTED PATIENTS
  474. 1335 IL28B POLYMORPHISM IN HIV-POSITIVE PATIENTS WITH ACUTE HEPATITIS C
  475. 1321 DIFFERENT INFLUENCE OF HCV-SPECIFIC T-CELL RESPONSES AND RS12979860 IL28B GENOTYPES ON KINETICS OF HCV CLEARANCE IN PATIENTS TREATED WITH PEGINTERFERON-RIBAVIRIN
  476. 354 LIVER FIBROSIS PROGRESSION IN HIV+ PATIENTS UNDER DISTINCT ANTIRETROVIRAL DRUGS
  477. 1338 WHOLE GENOME EXPRESSION PROFILE DEFINES DIFFERENTIALLY EXPRESSED GENES IN HIV/HCV-COINFECTED PATIENTS ACCORDING TO PEGIFNA/RBV TREATMENT OUTCOME AND TO IL28B GENOTYPE
  478. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients
  479. Elite Controllers Display Higher Activation on Central Memory CD8 T Cells Than HIV Patients Successfully on HAART
  480. Noncirrhotic portal hypertension in HIV infection
  481. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy
  482. HCV and HIV Coinfection
  483. A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters
  484. Sub-Cellular Distribution and Translocation of TRP Channels
  485. Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care
  486. Predicted effect of direct acting antivirals in the current HIV–HCV-coinfected population in Spain
  487. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues
  488. HBV primary drug resistance in newly diagnosed HIV–HBV-coinfected individuals in Spain
  489. Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study
  490. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline
  491. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV–HCV-coinfected patients
  492. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
  493. Resistance data in the ARTEN trial
  494. Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS)
  495. Infrared Focal Plane Array Imaging System Characterization by Means of a Blackbody Radiator
  496. Resistance data in the ARTEN trial
  497. Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain
  498. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance
  499. Acute hepatitis C in HIV-infected individuals – recommendations from the NEAT consensus conference
  500. Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey
  501. Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV
  502. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes
  503. Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
  504. Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants
  505. Efficacy of Exercise in Reducing Depressive Symptoms across 5-HTTLPR Genotypes
  506. Influence of a Single Nucleotide Polymorphism at the Main Ribavirin Transporter Gene on the Rapid Virological Response to Pegylated Interferon–Ribavirin Therapy in Patients with Chronic Hepatitis C Virus Infection
  507. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients
  508. Near-Membrane Dynamics and Capture of TRPM8 Channels within Transient Confinement Domains
  509. Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
  510. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study
  511. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe
  512. European guideline for the management of hepatitis B and C virus infections, 2010
  513. Elevated TGF-β1 levels might protect HCV/ HIV-coinfected patients from liver fibrosis
  514. Evolution of the Functional Profile of HIV-Specific CD8+ T Cells in Patients With Different Progression of HIV Infection Over 4 Years
  515. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis
  516. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
  517. Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)
  518. Situación actual de la infección por el virus de la inmunodeficiencia humana tipo 2 y el Virus linfotrópico de células T humano en España
  519. Prevalence of HTLV-1/2 Infections in Spain: A Cross-Sectional Hospital-Based Survey
  520. RETRACTED ARTICLE: Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial
  521. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies
  522. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists--authors' response
  523. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study
  524. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
  525. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
  526. Resistance to Integrase Inhibitors
  527. Low-Level Exposure to HIV Induces Virus-Specific T Cell Responses and Immune Activation in Exposed HIV-Seronegative Individuals
  528. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701
  529. Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010)
  530. Nuevos retrovirus humanos
  531. Infección por el virus de la inmunodeficiencia humana de tipo 2 (VIH-2) y los virus linfotrópico humano de células T de tipos 1 y 2 (HTLV-1/2) en España
  532. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia
  533. Plitidepsin (APL) alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM).
  534. Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy
  535. Glomerular filtration (GF) determined by creatinine clearance (CCR) in 24 hours urine and cockcroft & gault (cg) and modification of diet in renal disease (MDRD) equations in a large cohort of HIV+ patients
  536. Hepatitis B: treatment strategies and resistance
  537. Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption
  538. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients
  539. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings
  540. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists
  541. Renal toxicity associated with tenofovir use
  542. Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study
  543. Infección por el virus de la inmunodeficiencia humana en diferentes grupos de edad: implicaciones potenciales para la prevención. Cohorte CoRIS, España, 2004–2008
  544. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
  545. Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C
  546. 275 TREATMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS WITH COMPENSATED LIVER CIRRHOSIS
  547. 1008 KIDNEY TUBULAR DYSFUNCTION (KTD) IN PATIENTS WITH PROLONGED EXPOSURE TO TENOFOVIR (TDF): A PROSPECTIVE STUDY
  548. 1159 NON-CIRRHOTIC PORTAL HYPERTENSION IN HIV-INFECTED PATIENTS: UNIQUE CLINICAL AND PATHOLOGICAL FEATURES
  549. 1160 HEPATIC SAFETY PROFILE OF NEW ANTIRETROVIRAL DRUGS IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C
  550. 282 A SPECIFIC HAPLOTYPE AT THE ENT1 GENE INFLUENCES THE RATE OF SUSTAINED VIROLOGICAL RESPONSE TO PEGINTERFERON-RIBAVIRIN IN HIV/HCV-COINFECTED PATIENTS
  551. 715 ASSESSMENT OF THE VIROLOGICAL PROFILES OF UNTREATED PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD) REQUIRES LONGITUDINAL MEASUREMENTS OF HBV DNA AND HDV RNA
  552. 743 NATURALLY OCCURRING DRUG RESISTANCE MUTATIONS IN THE HEPATITIS C VIRUS NS3 PROTEASE IN HIV/HCV COINFECTED PATIENTS TREATED WITH HIV PROTEASE INHIBITORS
  553. 1085 VIRAL HEPATITIS B AND C IN NEWLY DIAGNOSED HIV-1 INDIVIDUALS IN SPAIN – A NATIONAL SURVEY SINCE YEAR 2000
  554. Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption
  555. Human immunodeficiency virus and liver disease: Conference proceedings
  556. Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse
  557. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients
  558. Survival of HIV-infected patients with compensated liver cirrhosis
  559. The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring
  560. Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
  561. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change
  562. Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C
  563. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients
  564. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe
  565. Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia
  566. Impact of baseline HIV-1 tropism on viral response and CD4 gains in antiretroviral-naïve patients
  567. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing
  568. Do interleukin-28B single nucleotide polymorphisms influence the natural history of chronic hepatitis B?
  569. No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV
  570. Efficacy and safety of TDF+FTC+EFV in naïve patients initiating HAART; an observational study comparing Atripla Vs Truvada/Sustiva exposure
  571. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome
  572. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
  573. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database
  574. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor
  575. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy
  576. Viral hepatitis and HIV co-infection
  577. TRPM8 Near-Membrane Dynamics and Channel Stabilization after Stimulation
  578. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C
  579. New therapeutic strategies for raltegravir
  580. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection
  581. Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations
  582. Short Communication: Transmission of Hepatitis B Viruses with Lamivudine Resistance Mutations in Newly Diagnosed HIV Individuals
  583. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection
  584. Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV‐Infected and HIV‐Uninfected Patients
  585. El desafío de la nueva gripe A/H1N1
  586. When and how to use maraviroc in HIV-infected patients
  587. Interleukin-2 Therapy in Patients with HIV Infection
  588. Fe de errores de “Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización febrero de 2009)”
  589. Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain
  590. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity
  591. Pharmacogenetics of tenofovir treatment
  592. Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource‐Limited Settings
  593. First HAART in HIV-Infected Patients With High Viral Load: Value of HIV RNA Levels at 12 Weeks to Predict Virologic Outcome
  594. Update on HIV viral-load assays: new technologies and testing in resource-limited settings
  595. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy
  596. Actualización sobre las infecciones por el virus de la inmunodeficiencia humana de tipo 2 y por los virus linfotrópico humano de tipo 1 y de tipo 2 en España
  597. Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients
  598. HIV protease inhibitors: recent clinical trials and recommendations on use
  599. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance
  600. Predictors of Kidney Tubular Dysfunction in HIV‐Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
  601. Seroprevalence of HTLV-1/2 Infection among Native and Immigrant Pregnant Women in Spain
  602. Seroreversion of Hepatitis C Virus (HCV) Antibodies in an HIV‐Infected Patient despite Continuous HCV Replication
  603. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
  604. Reply to Pascual Pareja et al.
  605. The role of injection versus socioeconomic factors in hepatitis A virus infection among young heroin users: Implications for vaccination policies
  606. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools
  607. Metodología de reclutamiento y características de una cohorte de jóvenes consumidores habituales de cocaína de tres ciudades españolas (Proyecto Itínere-cocaína)
  608. Variable Impact on Mortality of AIDS‐Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS‐Defining Conditions Are Created Equal
  609. 227 NON-CIRRHOTIC PORTAL HYPERTENSION IN HIV-INFECTED PATIENTS
  610. Differences in Lopinavir Plasma Concentrations Comparing Kaletra® Film Coated Tablets and Soft Gelatine Capsules That Result in Various Lipid Abnormalities
  611. Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización febrero de 2009)
  612. Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression
  613. Liver Complications Have Reached a Plateau as Cause of Hospital Admission and Death in HIV Patients in Madrid
  614. Transmisión vertical del virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad
  615. 343 NO EVIDENCE FOR LOW-LEVEL HCV REPLICATION OR SIGNIFICANT LIVER FIBROSIS IN HIV PATIENTS WHO SPONTANEOUSLY CLEARED HCV INFECTION
  616. 648 DIFFERENCES IN ANTIVIRAL ACTIVITY AND TOLERABILITY BETWEEN PEGYLATED INTERFERON ALPHA – 2A AND – 2B IN HIV INFECTED PATIENTS WITH CHRONIC HEPATITIS C
  617. 888 ASSOCIATION BETWEEN NAIVE REGULATORY T (TREG) CELLS AND HCV-SPECIFIC IMMUNE RESPONSES IN PATIENTS WITH CHRONIC HEPATITIS C
  618. 887 HCV-SPECIFIC T CELL RESPONSE IN PATIENTS WITH CHRONIC HIV/HCV CO-INFECTION IS NOT DEPENDENT OF HCV GENOTYPE
  619. 411 HEPATITIS C VIRUS REAPPEARANCE IN HIV-INFECTED PATIENTS WITH SPONTANEOUS HCV-RNA CLEARANCE
  620. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists
  621. Delayed Diagnosis of HIV Infection in a Multicenter Cohort: Prevalence, Risk Factors, Response to HAART and Impact on Mortality
  622. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
  623. Lack of Significant Cross-Reactivity for HIV-2 Immunoblots in HIV-1-Infected Patients
  624. Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests
  625. Fourth HIV & Hepatitis Coinfection Workshop; June 19–21, 2008; Madrid, Spain
  626. Prevalence of HLA-B*5701 in HIV-Infected Patients in Spain (Results of the EPI Study)
  627. New Therapies for Hepatitis C Virus Infection
  628. Raltegravir and Etravirine Are Active against HIV Type 1 Group O
  629. Non-covalent functionalization of carbon nanotubes with glycolipids: glyconanomaterials with specific lectin-affinity
  630. Clinical Differences and Viral Diversity between Newly HIV Type 1-Diagnosed African and Non-African Patients in Spain (2005–2007)
  631. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program
  632. Injecting, Sexual Risk Behaviors and HIV Infection in Young Cocaine and Heroin Users in Spain
  633. Level, phenotype and activation status of CD4+FoxP3+regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus
  634. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients
  635. Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study
  636. Editorial Commentary:Risks and Benefits of Using Antiretroviral Therapy in HIV‐Infected Patients with Chronic Hepatitis B in Developing Regions
  637. Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients
  638. Resistencia viral y barrera genética de atazanavir
  639. Detergent resistant membrane-associated IDE in brain tissue and cultured cells: Relevance to Aβ and insulin degradation
  640. Down‐Regulation of Interleukin‐7 Receptor (CD127) in HIV Infection Is Associated with T Cell Activation and Is a Main Factor Influencing Restoration of CD4+Cells after Antiretroviral Therapy
  641. Recently acquired HIV infection in Spain (2003-2005): introduction of the serological testing algorithm for recent HIV seroconversion
  642. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
  643. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
  644. Diagnóstico de las infecciones por subtipos no B del VIH-1 y por VIH-2
  645. Optimal use of maraviroc in clinical practice
  646. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues
  647. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
  648. Resistencia a los inhibidores de la integrasa
  649. Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV‐Infected Patients with Anti‐HCV Antibodies in Europe
  650. Reliability of Rapid Subtyping Tools Compared to That of Phylogenetic Analysis for Characterization of Human Immunodeficiency Virus Type 1 Non-B Subtypes and Recombinant Forms
  651. Current trends in screening across ethnicities for hypersensitivity to abacavir
  652. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies
  653. Low Rate of Adverse Hepatic Events Associated with Fosamprenavir/Ritonavir-Based Antiretroviral Regimens
  654. Maraviroc: farmacocinética, interacciones y mecanismo de acción
  655. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4
  656. Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28–30, 2008
  657. Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C
  658. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone
  659. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C
  660. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy
  661. Short Communication: HIV Rebound after Discontinuation of Antiretroviral Therapy Increases and Expands HIV-Specific CD8+ Responses But Has No Impact on Its Functionality
  662. No Major Differences in the Functional Profile of HIV Gag and Nef-Specific CD8+ Reponses between Long-Term Nonprogressors and Typical Progressors
  663. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients
  664. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
  665. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
  666. Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants
  667. Increase of Non-B Subtypes and Recombinants Among Newly Diagnosed HIV-1 Native Spaniards and Immigrants in Spain
  668. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel
  669. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain
  670. Hepatitis C Virus Coinfection Does Not Affect CD4 Restoration in HIV-Infected Patients after Initiation of Antiretroviral Therapy
  671. Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years
  672. Management of Chronic Hepatitis C Virus Infection in HIV‐Infected Patients
  673. Performance of a Population-Based HIV-1 Tropism Phenotypic Assay and Correlation With V3 Genotypic Prediction Tools in Recent HIV-1 Seroconverters
  674. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements
  675. Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir
  676. Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir
  677. Hepatitis B vaccination: An unmet challenge in the era of harm reduction programs
  678. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy
  679. Papel de tenofovir en la coinfección por el virus de la inmunodeficiencia humana y el virus de la hepatitis C
  680. Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring
  681. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin
  682. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B
  683. Presentación
  684. Management of hepatitis B virus co-infection on and off antiretroviral therapy
  685. Profile of Patients Triply Infected with HIV and the Hepatitis B and C Viruses in the HAART Era
  686. Resistencias en el virus de la hepatitis B
  687. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8+ T cells
  688. A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1
  689. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
  690. Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid‐Lowering Drugs in HIV‐Infected Individuals and Impact on Myocardial Infarction
  691. Short Communication: Association between Tipranavir Plasma Levels and Virological Response in HIV-Infected Patients
  692. Emerging drugs for hepatitis C
  693. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes
  694. HIV-1 Infection in Persistently HIV-1-Seronegative Individuals: More Reasons for HIV RNA Screening
  695. Lobeline attenuates progressive ratio breakpoint scores for intracranial self-stimulation in rats
  696. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome
  697. Hepatitis B virus escape mutants induced by antiviral therapy
  698. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola
  699. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults
  700. The implications of antiviral drugs with activity against hepatitis B virus and HIV
  701. Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes
  702. Antiretroviral drugs and liver injury
  703. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
  704. Genetic characterization of complex inter-recombinant HIV-1 strains circulating in Spain and reliability of distinct rapid subtyping tools
  705. Initial spontaneous clearance and re-infection with a distinct hepatitis C virus genotype leading to chronic hepatitis C in an HIV+ intravenous drug user
  706. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance
  707. Prevalence of and Risk Factors for Hepatitis B Virus Infection among Street-Recruited Young Injection and Non-Injection Heroin Users in Barcelona, Madrid and Seville
  708. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C
  709. 698 NUCLEOS(T)IDE ANALOGUE TREATMENT FOR HBV INFECTIONS CAN RESULT IN THE SELECTION OF POSSIBLE HBV VACCINE ESCAPE MUTANTS
  710. 770 HCV RELAPSES UPON COMPLETION OF PEG-INTERFERON PLUS RIBAVIRIN IN HIV-INFECTED PATIENTS: RATE, TIMING AND PREDICTORS
  711. 801 RESCUE THERAPY WITH OPTIMIZED PEG-INTERFERON PLUS RIBAVIRIN IN HIV/HCV COINFECTED PATIENTS: CRITICAL ROLE OF RIBAVIRIN PLASMA LEVELS IN THE PILOT-NR TRIAL
  712. 838 DISTINCT HEPATITIS C VIRUS KINETICS IN HIV+ PATIENTS TREATED WITH RIBAVIRIN PLUS EITHER PEGYLATED INTERFERON ALFA-2A OR ALFA-2B
  713. 708 POLYMORPHISMS WHICH MAY BE RESPONSIBLE FOR PRIMARY TREATMENT FAILURE TO ADEFOVIR IN DISTINCT HEPATITIS B VIRUS GENOTYPES
  714. 606 RELATIONSHIP BETWEEN THE STAGE OF LIVER FIBROSIS AND REGULATORY T (TREG) CELLS IN PATIENTS WITH CHRONIC HEPATITIS C COINFECTED WITH HIV
  715. The changing epidemiology of hepatitis C virus infection in Europe
  716. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years
  717. Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy
  718. Measurement of Ribavirin Plasma Concentrations by High-performance Liquid Chromatography Using a Novel Solid-phase Extraction Method in Patients Treated for Chronic Hepatitis C
  719. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
  720. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART
  721. Human T Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis in an HIV-Positive Patient Coinfected with Human T Lymphotropic Virus Type 2 Following Initiation of Antiretroviral Therapy
  722. Management and therapy of chronic hepatitis C in HIV
  723. Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity
  724. Value of the HLA-B*5701 Allele to Predict Abacavir Hypersensitivity in Spaniards
  725. Linear IgA bullous dermatosis associated with systemic lupus erythematosus: a case report
  726. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials
  727. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors
  728. Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study
  729. Respuesta inmunitaria celular adaptativa frente a la infección por el virus de la hepatitis C
  730. Lack of anti-HIV activity of entecavir in an HIV patient coinfected with hepatitis B and delta viruses
  731. Large lymphadenopathies complicating the abacavir hypersensitivity reaction
  732. Short Communication: Dynamics of Drug-Resistant HIV-1 in Plasma and Peripheral Blood Cells in Patients during and after Enfuvirtide Therapy
  733. Amino Acid Conservation in the gp41 Transmembrane Protein and Natural Polymorphisms Associated with Enfuvirtide Resistance across HIV-1 Variants
  734. Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV‐Infected Patients
  735. Short Communication: Hospital-Based Surveillance for HTLV-1/2 Infections in Spain
  736. Estavudina en el tratamiento antirretroviral
  737. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome
  738. Churg-Strauss syndrome triggered by hyposensitization to Alternaria fungus
  739. Baseline Serum Hepatitis C Virus (HCV) RNA Level and Response at Week 4 Are the Best Predictors of Relapse After Treatment With Pegylated Interferon Plus Ribavirin in HIV/HCV-Coinfected Patients
  740. Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial
  741. Escape Mutations in HIV Infection and its Impact on CD8+ T Cell Responses
  742. Authors?? Reply to ???How Safe Is Unprotected Sex Between Discordant Couples to Conceive in the Highly Active Antiretroviral Therapy Era????
  743. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection
  744. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors
  745. Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients
  746. Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use
  747. Impact of Ethnicity and HIV Type 1 Subtype on Response to First-Line Antiretroviral Therapy
  748. Is natural conception a valid option for HIV-serodiscordant couples?
  749. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
  750. Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors
  751. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis
  752. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients
  753. Infección por el virus de la inmunodeficiencia humana tipo 2 y virus linfotrópicos humanos tipos 1 y 2 en España
  754. Liver Fibrosis Stage and HCV Genotype Distribution in HIV–HCV Coinfected Patients with Persistently Normal Transaminases
  755. Consejo reproductivo en parejas serodiscordantes para el virus de la inmunodeficiencia humana
  756. Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation
  757. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel
  758. Telbivudine: a new option for the treatment of chronic hepatitis B
  759. C2-Symmetric Bissulfoxides as Organocatalysts in the Allylation of Benzoyl Hydrazones:  Spacer and Concentration Effects
  760. Evolution of T-cell Responses to Hepatitis C Virus (HCV) during Pegylated Interferon plus Ribavirin treatment in HCV-Monoinfected and in HCV/HIV-Coinfected Patients
  761. Treatment of Chronic Hepatitis B or C in HIV‐Infected Patients with Dual Viral Hepatitis
  762. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
  763. Hepatitis B Virus Genotypes and Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients
  764. [591] IMPACT OF ANEMIA AND ZIDOVUDINE USE ON SUSTAINED VIROLOGICAL RESPONSE IN A TRIAL OF PEGYLATED INTERFERON PLUS RIBAVIRIN IN HIV/HCV-COINFECTED PATIENTS
  765. Evaluation of performance across the dynamic range of the Abbott RealTime™ HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses
  766. Influence of Liver Fibrosis Stage on Plasma Levels of Antiretroviral Drugs in HIV‐Infected Patients with Chronic Hepatitis C
  767. Introduction of Non-B Subtypes among Spaniards Newly Diagnosed with HIV Type 1 in the Canary Islands
  768. Outbreak of Syphilis, but Not of Acute Hepatitis C, Among HIV-Infected Homosexual Men in Madrid
  769. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients
  770. [188] INFLUENCE OF ANTIRETROVIRALS IN THE PROGRESSION OF LIVER FIBROSIS IN HIV/HCV COINFECTED PATIENT S. EFFECT OF HEPATOTOXICITY AND METABOLIC ABNORMALITIES
  771. [512] HEPATITIS B VIRUS MUTANTS IN PATIENTS FAILING ANTIRETROVIRALS WITH ANTI-HBV ACTIVITY: IMPLICATIONS FOR DIAGNOSTICS AND VACCINE ESCAPE
  772. [616] BASELINE HCVRNA AND RAPID VIROLOGICAL DECAY ARE THE MAIN PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE IN HIV-HCV COINFECTED PATIENTS
  773. [697] LIVER FIBROSIS IN HIV-INFECTED PATIENTS WITHOUT CHRONIC VIRAL HEPATITIS. PREVALENCE, CLINICAL CHARACTERISTICS AND POTENTIAL CAUSES
  774. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment
  775. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy
  776. Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients
  777. P1899 Assessment of liver cirrhosis by elastography in HCV/HIV co–infected patients
  778. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance
  779. Recomendaciones españolas sobre el uso adecuado de enfuvirtida
  780. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients
  781. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma
  782. Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide
  783. Adult neurogenesis and schizophrenia: A window on abnormal early brain development?
  784. Drug Interactions of Tipranavir, a New HIV Protease Inhibitor
  785. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
  786. Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus
  787. Influence of Human T Cell Lymphotropic Virus Type 2 Coinfection on Virological and Immunological Parameters in HIV Type 1–Infected Patients
  788. Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy “don’t ask, draw a blood sample, vaccinate and try to schedule another visit”
  789. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy
  790. Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): metodología y primeros resultados
  791. Aplicación de modelos estructurales marginales para estimar los efectos de la terapia antirretroviral en 5 cohortes de seroconvertores al virus de la inmunodeficiencia humana
  792. Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression
  793. Rate of Virologic Failure and Selection of Drug Resistance Mutations Using Different Triple Nucleos(t)ide Analogue Combinations in HIV-Infected Patients
  794. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002
  795. Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1)
  796. Natural Pregnancies in HIV-Serodiscordant Couples Receiving Successful Antiretroviral Therapy
  797. Coinfection with Hepatitis C Virus Increases Lymphocyte Apoptosis in HIV-Infected Patients
  798. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin
  799. Chemoprophylaxis with Tenofovir Disoproxil Fumarate Provided Partial Protection against Infection with Simian Human Immunodeficiency Virus in Macaques Given Multiple Virus Challenges
  800. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection
  801. Implicaciones diagnósticas, clínicas y terapéuticas de las hepatitis virales en el paciente infectado por el VIH
  802. Infecciones por VIH-2 y HTLV-1/2 en España
  803. Tratamiento de la hepatitis crónica B en pacientes infectados por el VIH
  804. Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV Activity
  805. Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: gender differences and other related factors
  806. Impact of Antiretroviral Treatment-Related Toxicities on Hospital Admissions in HIV-Infected Patients
  807. Impact of Gag Sequence Variability on Level, Phenotype, and Function of Anti-HIV Gag-Specific CD8+ Cytotoxic T Lymphocytes in Untreated Chronically HIV-Infected Patients
  808. ¿Se debería recomendar el cribado de la infección por el virus linfotrópico humano de células T de tipo 1 en las mujeres embarazadas?
  809. Virological Outcome of Chronic Hepatitis B Virus Infection in HIV-Coinfected Patients Receiving Anti-HBV Active Antiretroviral Therapy
  810. Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus
  811. Immunological and Virological Effects of Structured Treatment Interruptions following Exposure to Hydroxyurea Plus Didanosine
  812. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure
  813. Performance of Six Different Ritonavir-Boosted Protease Inhibitor–Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients
  814. Mutations affecting the replication capacity of the hepatitis B virus
  815. Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors
  816. Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs
  817. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors
  818. Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes
  819. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART
  820. Coinfección por el VIH y el virus de la hepatitis C
  821. Management of chronic hepatitis B and C in HIV-coinfected patients
  822. External Validation of Atazanavir/Ritonavir Genotypic Score in HIV-1 Protease Inhibitor-Experienced Patients
  823. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
  824. Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3
  825. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance
  826. 574 Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients
  827. 421 Hepatitis C virus (HCV)-specific CD4+ and CD8+ T cell responses in patients with chronic hepatitis C treated with pegylated interferon plus ribavirin
  828. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir
  829. The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes
  830. Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less
  831. Entrada del virus de la inmunodeficiencia humana en las células: mecanismos y posibilidades terapéuticas
  832. HTLV infection among young injection and non-injection heroin users in Spain: Prevalence and correlates
  833. Standard of Care for HCV/HIV-Coinfected Patients
  834. HIV entry inhibitors: mechanisms of action and resistance pathways
  835. Overview of the pharmacogenetics of HIV therapy
  836. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy
  837. Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent
  838. Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive HIV-Infected Patients
  839. Tratamiento antirretroviral en la infección por el virus de la inmunodeficiencia humana: ¿cuánto dura su eficacia?
  840. Respuesta de los autores
  841. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons
  842. Variability in the P6gag domains of HIV-1 involved in viral budding
  843. Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1
  844. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART
  845. Can the Level of Immunosuppression in Human Immunodeficiency Virus-Infected Patients Affect the Reliability of Human T-Cell Lymphotropic Virus Type 2 Serological Diagnosis?
  846. Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain
  847. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C
  848. Treatment of chronic hepatitis C in HIV-positive individuals: Selection of candidates
  849. Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV Activity
  850. CD4+T Cell Recovery beyond the First Year of Complete Suppression of Viral Replication during Highly Active Antiretroviral Therapy Is Not Influenced by CD8+T Cell Activation
  851. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
  852. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy
  853. Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfected Population Followed at a Reference HIV Center
  854. Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America
  855. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder
  856. New paradigms in the management of HIV and hepatitis C virus coinfection
  857. Phage Display Selection of HIV Specific Conserved Mimotopes With IgG from Long-term Non-progressors
  858. Complications in treating chronic hepatitis B in patients with HIV
  859. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir
  860. Genetic Analysis of Regulatory, Promoter, and TAR Regions of LTR Sequences Belonging to HIV Type 1 Non-B Subtypes
  861. Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain
  862. Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study
  863. Differences in the Length of Gag Proteins among Different HIV Type 1 Subtypes
  864. Failure of Hepatitis C Therapy in HIV‐Coinfected Drug Users Is Not Due to a Shift in Hepatitis C Virus Genotype
  865. Hepatic and Renal Safety Profile of Tenofovir in HIV-Infected Patients with Hepatitis C, Including Patients on Interferon Plus Ribavirin
  866. Sustained Virological Response following HCV Therapy is Associated with Non-Progression of Liver Fibrosis in HCV/HIV-Coinfected Patients
  867. Prevalence of Drug‐Resistant HIV‐1 Variants in Untreated Individuals in Europe: Implications for Clinical Management
  868. Influence of Hepatitis C Virus Infection on HIV‐1 Disease Progression and Response to Highly Active Antiretroviral Therapy
  869. Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption
  870. Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group
  871. Clinical benefit of interventions driven by therapeutic drug monitoring
  872. HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003
  873. Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection
  874. Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT
  875. Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients
  876. Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity
  877. Antiretroviral Recommendations May Influence the Rate of Transmission of Drug‐Resistant HIV Type 1
  878. Viral Response to Antiretroviral Therapy in a Patient Coinfected with HIV Type 1 and Type 2
  879. Erratum
  880. Liver Transplantation in HIV–HCV Coinfected Candidates: What Is the Most Appropriate Time for Evaluation?
  881. Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma
  882. Treatment Response and Drug Resistance in Patients Infected with HIV Type 1 Group O Viruses
  883. Short Communication: Changes in Nevirapine Plasma Concentrations Over Time and Its Relationship with Liver Enzyme Elevations
  884. Enfuvirtide Is Active against HIV Type 1 Group O
  885. Management of patients co-infected with hepatitis B virus and HIV
  886. Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping Due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection
  887. Outmoded Attitudes Toward Organ Donation Among Turkish Health Care Professionals
  888. Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects
  889. Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain
  890. Estrategias terapéuticas en la infección por el virus de la inmunodeficiencia humana
  891. Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration
  892. Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain
  893. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel
  894. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients
  895. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine
  896. Situación actual de la infección por el VIH-2 y el HTLV-1/2 en España: luces y sombras
  897. Differential Upregulation of CD38 on Different T-Cell Subsets May Influence the Ability to Reconstitute CD4+ T Cells Under Successful Highly Active Antiretroviral Therapy
  898. Hepatitis C Viremia in HIV/HCV-Coinfected Patients: Lower Levels in Presence of Chronic Hepatitis B
  899. Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive patients
  900. Relationship between drug resistance mutations, plasma viremia, and CD4+T-cell counts in patients with chronic HIV infection
  901. Regulación de la transcripción en los diferentes subtipos del VIH-1
  902. Risks and benefits of antiretroviral therapy in HIV–HCV co-infected patients
  903. Association of CCR5 Human Haplogroup E with Rapid HIV Type 1 Disease Progression
  904. Atazanavir: The Advent of a New Generation of More Convenient Protease Inhibitors
  905. Estimated Extent of Cross-Resistance to Ritonavir-Boosted Protease Inhibitors Among Protease Inhibitors-Experienced Patients: Implications for Tipranavir Use
  906. Hepatitis C y VIH en prisiones españolas
  907. Natural history of Hymenoptera venom allergy in Eastern Spain
  908. Heterogeneous nature of HIV-1 recombinants spreading in Spain
  909. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients
  910. Hepatotoxicity of Antiretrovirals
  911. Hepatitis C Virus (HCV) Genotypes and Disease Progression in HIV/HCV‐Coinfected Patients
  912. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients
  913. The Seroepidemiology of Human T-Lymphotropic Viruses
  914. Absceso cerebral en paciente inmunodeprimida
  915. Short Communication: Benefits in the Lipid Profile after Substitution of Abacavir for Stavudine: A 48-Week Prospective Study
  916. Hepatocellular carcinoma in HIV-infected patients
  917. Avances en el diagnóstico y tratamiento de la infección por el virus de la hepatitis B
  918. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes
  919. Evidence for Differences in the Sexual Transmission Efficiency of HIV Strains with Distinct Drug Resistance Genotypes
  920. Prevalence of HIV-1 non-B subtypes, syphilis, HTLV, and hepatitis B and C viruses among immigrant sex workers in Madrid, Spain
  921. Comments on the review ‘Care of patients with hepatitis C and HIV co-infection’ by Soriano et al.
  922. Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals
  923. Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations
  924. How effective is HAART in HCV and HIV coinfection?
  925. Predictors of selection of K65R
  926. Reply to Bruno et al.
  927. Failure to Detect Human Immunodeficiency Virus Type 1 Superinfection in 28 HIV-Seroconcordant Individuals with High Risk of Reexposure to the Virus
  928. Triple-Nucleoside Regimens versus Efavirenz
  929. Resistance to HIV Protease Inhibitors: Mechanisms and Clinical Consequences
  930. New Hopes for HIV and HCV Coinfection in 2004
  931. Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients
  932. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure
  933. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
  934. Short Communication: Liver Toxicity of Lopinavir-Containing Regimens in HIV-Infected Patients with or without Hepatitis C Coinfection
  935. Reply
  936. Predictors of Severe Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C
  937. CD4+ T-Cell Gain With Nonnucleoside or Protease Inhibitors: Convenience May Not Always Be the Most Convenient
  938. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea
  939. Impact of Chronic Hepatitis C on HIV-1 Disease Progression
  940. Tolerance of Didanosine as Enteric-Coated Capsules versus Buffered Tablets
  941. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide
  942. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection
  943. Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected Patients
  944. Tenofovir-related nephrotoxicity in HIV-infected patients
  945. Prevalencia de infección por virus de transmisión parenteral en consumidores actuales de heroína de 3 ciudades españolas
  946. Simplificación de los regímenes antirretrovíricos. Una necesidad para garantizar el control de la infección por VIH a largo plazo
  947. Infecciones por VIH-2 y HTLV-I/II en España
  948. Are Fusion Inhibitors Active against All HIV Variants?
  949. Changes in Mitochondrial DNA Copy Number in Blood Cells from HIV-Infected Patients Undergoing Antiretroviral Therapy
  950. Prediction of Virological Response to Lopinavir/Ritonavir Using the Genotypic Inhibitory Quotient
  951. Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues
  952. Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations
  953. Analyzing Sleep Abnormalities in HIV‐Infected Patients Treated with Efavirenz
  954. CD38 Expression on CD8 T Lymphocytes as a Marker of Residual Virus Replication in Chronically HIV-Infected Patients Receiving Antiretroviral Therapy
  955. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1
  956. Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus–Infected Patients with Chronic Hepatitis C: A European Collaborative Study
  957. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations
  958. Care of patients with hepatitis C and HIV co-infection
  959. Impact of Drug Levels and Baseline Genotype and Phenotype on the Virologic Response to Amprenavir/Ritonavir-Based Salvage Regimens
  960. Management of Chronic Hepatitis C in Patients Co-Infected with HIV
  961. Modifications in SENV DNA Detection and/or SENV Subtype Determination over a Prospective Follow-Up in a Cohort of HIV-Positive Patients: Is This a Moving Target?
  962. 391 Association between HCV-specific CD8+ T cell responses and levels of viral replication in patients chronically infected with HCV
  963. 262 Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients
  964. Hepatitis E in the south west of France in individuals who have never visited an endemic area
  965. Treatment of Chronic Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Present and Future
  966. Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α -2b Plus Ribavirin
  967. Hydroxyurea plus Didanosine as Maintenance Therapy for HIV-Infected Patients on Long-Term Successful Highly Active Antiretroviral Therapy
  968. Long-Term Outcome of HIV-Infected Patients with Multinucleoside-Resistant Genotypes
  969. SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression
  970. Book Review
  971. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
  972. Phenotype and Functional Characteristics of HIV-Specific Cytotoxic CD8+ T Cells in Chronically Infected Patients
  973. Diarrhea Related to Lopinavir Is Most Often Mild and Not Related to Plasma Drug Levels
  974. Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients
  975. Toxicidad mitocondrial de los antirretrovirales: diagnóstico y monitorización
  976. Correlation Between Lopinavir Plasma Levels and Lipid Abnormalities in Patients Taking Lopinavir/Ritonavir
  977. Gynecomastia in HIV-Infected Patients Receiving Antiretroviral Therapy
  978. Virus Load and Cytolitic Responses in Human Immunodeficiency Virus Infection: What Is Cause and What Is Effect
  979. Distribution of Hepatitis B Virus Genotypes in HIV-Infected Patients with Chronic Hepatitis B: Therapeutic Implications
  980. Impact of Hepatitis C Virus (HCV) on Morbidity and Mortality Rates among HIV-Infected Patients
  981. Replacement of Protease Inhibitors by Nevirapine or Efavirenz in Simplification and Rescue Interventions: Which Works Better?
  982. Can Drug Resistance Mutations Influence the Measurement of Plasma HIV-RNA by Different Viral Load Techniques?
  983. Superinfección por el virus de la inmunodeficiencia humana: implicaciones clínicas y biológicas
  984. Indinavir Plasma Concentrations and Resistance Mutations in Patients Experiencing Early Virological Failure
  985. Transmission of HIV Type 1 through Blood Transfusion from an Antibody-Negative/p24 Antigen-Negative Donor
  986. Secuencias largas terminales repetidas de los retrovirus: estructura y función
  987. Lamivudine Resistance in Human T-Cell Leukemia Virus Type 1 May Be Due to a Polymorphism at Codon 118 (V->I) of the Reverse Transcriptase
  988. HIV-Positive Immigrants in the Canary Islands, Spain: Implications for Public Health in Europe
  989. Human immunodeficiency virus type 1 recombinant B/G subtypes circulating in Coimbra, Portugal
  990. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
  991. Rate, Causes, and Clinical Implications of Presenting with Low CD4+ Cell Counts in the Era of Highly Active Antiretroviral Therapy
  992. Histological damage in liver biopsy specimens from 492 HIV-HCV co-infected patients: A European collaborative study
  993. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy
  994. Is Treatment Failure for Hepatitis C Virus Infection in HIV-Positive Drug Users Associated With a Shift in HCV Genotypes?
  995. Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients
  996. Performance of drug resistance assays in testing HIV-1 non-B subtypes
  997. Hepatitis C virus (HCV) relapses following the end of anti-HCV therapy are more frequent in HIV-coinfected patients
  998. Predictive value of early virological response (12 weeks) to pegylated interferon plus ribavirin in HIV-HCV coinfected patients
  999. Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated Patients
  1000. Avascular Necrosis in HIV-Infected Patients Receiving Antiretroviral Treatment: Study of Seven Cases

Showing 1,000 Stories.